3 Reasons Why You Should Sell Shire PLC

Shire PLC (LON:SHP) shareholders should heed the lessons of Pfizer’s bid for AstraZeneca plc (LON:AZN), says Roland Head.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

shireShire (LSE: SHP) (NASDAQOTH: SHPG.US) shareholders have seen the value of their stock rise by 60% this year, thanks mainly to a takeover bid from US firm AbbVie.

However, Shire’s management is currently playing hardball, by claiming that the bid “fundamentally undervalues the company and its prospects”.

If you’re a Shire shareholder, you may think that the correct approach is to sit tight and wait for AbbVie to make a higher offer — and they might. However, I’m not sure the figures support a higher bid.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

1. Isn’t Shire worth more?

The main claim made by Shire’s board to justify a higher valuation is that Shire’s sales will double to $10bn by 2020.

Assuming the firm maintains its historic post-tax profit margin of around 17%, this means that net income could rise to around $1.7bn by 2020. If we generously round this up to $2.5bn to allow for acquisitions, then Shire’s current share price equates to a 2020 forecast P/E of almost 18!

I reckon that’s a very generous valuation indeed.

2. Are you a gambler?

AstraZeneca‘s (LSE: AZN) (NYSE: AZN.US) share price fell by 11% in one day after the Pfizer bid fell through.

The failure of the bid disappointed a lot of AstraZeneca investors, but as I wrote at the time, they really only had themselves to blame: if they wanted cash, they should have sold.

Waiting for a higher offer is a big gamble: one of the key principles of successful investing, in my view, is always to leave something on the table for the next person.

I mention all of this because I suspect that the same thing could happen with the current Shire bid — except here, the potential downside, post-bid, is much greater than it was with AstraZeneca:

Valuation before bid AstraZeneca Shire
2014 forecast P/E 15.2 17.9
Prospective yield 4.5% 0.5%
Peak valuation during bid    
2014 forecast P/E 19.2 23.4
Prospective yield 3.5% 0.4%

Source: Reuters analysts’ consensus forecasts

Shire has been touted as a bid target for years — but now that a decent bid has appeared, shareholders might not be so patient in the future, if this bid is allowed to fall through.

Shire’s yield is virtually zero, so the only reason to hold the stock is for capital gains. In my view, Shire’s share price could fall dramatically if the firm’s board allows this bid to fall through.

3. You should sell

Shire’s share price is 4,579p as I write, only fractionally below the 4,611p value of AbbVie’s bid.

In my view, selling carries much less risk than continuing to hold, and is the only sensible decision for most shareholders.

Pound coins for sale — 31 pence?

This seems ridiculous, but we almost never see shares looking this cheap. Yet this Share Advisor pick has a price/book ratio of 0.31. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 31p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 10%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Roland does not own shares in any of the companies mentioned in this article. The Motley Fool has recommended shares in Shire.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

3 FTSE 100 investment trusts to consider for a new ISA in 2025

It's a new tax year and time to dust off that old ISA. Here are three FTSE 100 investment trusts…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Is there still time to pick up Nvidia stock cheaply?

The Nvidia stock price has just had a scary week. But here's why I expect that should have very little…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Investors considering Legal & General shares could aim for £10,075 a year in passive income from a £5,500 stake!

Legal & General shares deliver one of the highest yields of any major FTSE-listed firm, so investing now could generate…

Read more »

Investing Articles

Is it game over for Rolls-Royce shares after the biggest single-week fall since Covid?

In the first week of April, the Rolls-Royce share price suffered its largest single-week drop since Covid. Our writer ponders…

Read more »

Investing Articles

Here’s why the IAG share price could rally to 300p again soon!

The IAG share price has been decimated in recent weeks with airline stocks caught up in the broader volatility. However,…

Read more »

Investing Articles

Here’s how to produce a £1,400 second income from a £20k ISA in the next year

Harvey Jones says it's possible to generate a second income of £1,400 from this year's Stocks and Shares ISA. It…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

The BP share price keeps falling. But should I put the energy giant in my SIPP?

Our writer looks at the recent BP share price performance and considers whether it would be a good addition to…

Read more »

Investing Articles

How much would an ISA investor need for an early retirement?

Even with the rising cost of living, regular investment in a Stocks and Shares ISA could help Britons retire before…

Read more »